[PERSON]
Mark A. Goldsmith
Featured in 2 tracked stories · first seen
Situations
FDA approves Rasonque for pancreatic cancer; lung cancer use
36 clusters · 292 sources · last updated
Latest: Daraxonrasib shows clinical promise for RAS-mutant lung cancer
On 26 August 2026, the U.S. Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, marketed as Rasonque, for treating adults with metastatic pancreatic ductal adenocarcinoma (PDAC). Developed by R
Also covered in
-
Royal Bank of Canada boosts stakes in Sanofi and Novo Nordisk
[BUSINESS] · 2 sources ·